SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide
Read the article

Memorial Sloan Kettering Cancer Center, New York
Dr. Charles Rudin is Director of Memorial Sloan Kettering Cancer Center in New York, where he previously served a decade as Chief of the Thoracic Oncology Service. His research focuses on the molecular biology and treatment of lung cancer, with particular emphasis on small-cell lung cancer (SCLC). He has led multiple practice-changing trials in SCLC and NSCLC and is widely recognized for his work on tumor heterogeneity and targeted-therapy resistance mechanisms.
Charles Rudin
Programme Roster